Drug Profile
Research programme: antibody therapeutics - GlaxoSmithKline
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antibodies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified